Current status of Japanese studies with the new anthracycline antibiotic aclacinomycin A.
Fundamental and clinical studies on a new yellow anthracycline antibiotic aclacinomycin A are reviewed. Favorable responses were seen in patients with acute leukemia refractory to daunomycin and adriamycin, malignant lymphoma, and breast, ovarian, lung, gastric, intestinal, and urinary bladder cancers by intravenous and intraperitoneal infusions or bladder instillation of aclacinomycin A alone in the phase II study.
D015250:Aclarubicin; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D007700:Kinetics; D009153:Mutagens; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D009153:Mutagens; D009279:Naphthacenes; D015250:Aclarubicin